Status:
ACTIVE_NOT_RECRUITING
Critical Care Outcomes of Hematologic Oncology Patients
Lead Sponsor:
Mount Sinai Hospital, Canada
Conditions:
Hematologic Malignancy
Stem Cell Transplant
Eligibility:
All Genders
16+ years
Brief Summary
Hematologic malignancy patients are admitted to ICU in increasing numbers. Successful ICU intervention has led to an increasing number of ICU survivors; however, there is a lack of information availab...
Detailed Description
At the time of ICU admission, the investigators will collect clinical data from the medical chart on a daily basis including demographics, pre-existing disease(s), treatment and reason for ICU admissi...
Eligibility Criteria
Inclusion
- Subjects \>16 years with Hematologic Malignancy (HM) or post Stem Cell Transplant (HCT) who require ICU admission.
- HM includes: acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myeloma, lymphoma, myelofibrosis, and other myeloproliferative disorders or myelodysplastic syndromes.
- HCT is defined as the transplantation of multipotent hematopoietic stem cells from bone marrow, peripheral blood, or umbilical cord blood.
Exclusion
- Subjects with significant preexisting neurological or psychiatric disease will be excluded from Phase 2 (1-year follow-up) but will be included in Phase 1.
Key Trial Info
Start Date :
February 26 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2026
Estimated Enrollment :
415 Patients enrolled
Trial Details
Trial ID
NCT03449953
Start Date
February 26 2018
End Date
December 31 2026
Last Update
November 27 2024
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Foothills Hospital
Calgary, Alberta, Canada, T2N 2T9
2
University of Alberta
Edmonton, Alberta, Canada, T6G 2R3
3
Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 1M9
4
University of Manitoba
Winnipeg, Manitoba, Canada, R3T 2N2